Double-Dose Firmonertinib Boosts EGFR L858R Lung Cancer Treatment
A groundbreaking advancement in the fight against non-small-cell lung cancer (NSCLC) has emerged from a recent multicenter phase II study ...
Tag: Double-dose therapy** **Reasoning:** 1. **Firmonertinib:** The primary drug being studied. 2. **EGFR L858R mutation:** The specific genetic target of the treatment. 3. **
